Vaccine-mediated control of bacterial virulence regulation and infection

疫苗介导的细菌毒力调节和感染控制

基本信息

批准号：
9981319
负责人：
Pamela Ranel Hall
金额：
$ 2.49万
依托单位：
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-01-01 至 2023-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9981319
关键词：
Active Immunization Address Affinity Alleles Alpha Particles Antibiotic Resistance Antibodies Antibody Response Antimicrobial Resistance Apolipoproteins B Atopic Dermatitis Binding Blood Cell physiology Centers for Disease Control and Prevention (U.S.)Chronic Granulomatous Disease Clinical Trials Community Hospitals Critical Illness Development Diabetes Mellitus DsRed Economic Burden Epitopes Failure Fluorescence Genetic Growth Health Human Image Immune Immunity Immunocompetent Immunosuppression Individual Infection Infectious Skin Diseases Intramuscular Job&apos s Syndrome Kinetics Life Lipase Luciferases Measures Mediating Methicillin Resistance Modeling Mus Nosocomial Infections Operon Outcome Passive Immunization Pathogenesis Patients Peptide Hydrolases Peptide Vaccines Peptides Pneumonia Pre-Clinical Model Production Recurrence Regulation Regulator Genes Reporter Role Signal Transduction Skin Tissue Soft Tissue Infections Source Staphylococcus aureus Staphylococcus aureus infection Stream Structure System Testing Therapeutic Toxin Trauma Vaccination Vaccines Virulence Virulence Factors Virus-like particle Western Blotting base cost design efficacy testing human disease immune function immunogenicity improved improved outcome in vitro Assay in vivo in vivo imaging insight luminescence methicillin resistant Staphylococcus aureus mouse model neutralizing antibody novel strategies novel vaccines pathogen patient population peptide vaccination pre-clinical prevent prophylactic protein-histidine kinase receptor vaccine candidate vaccine delivery vaccine development vaccine efficacy virtual

项目摘要

PROJECT SUMMARY: Staphylococcus aureus (SA), including methicillin-resistant (MRSA), is the most common cause of skin and soft tissue infection (SSTI) in the US. SA causes recurrent infections, particularly in highly susceptible patient populations with reduced immune function. To date, no vaccine to prevent SA infection has succeeded in human trials. Meanwhile, the need for a vaccine continues to escalate, as does the ability of this pathogen to acquire antibiotic resistance. We have developed a novel vaccine to control regulation of SA virulence factor production. In models of skin infection, this vaccine induces antibodies that prevent activation of this regulator system and protect against invasive infection. In this proposal, we aim to evaluate the preclinical potential of this vaccine strategy. We will determine vaccine efficacy in multiple models of SA infection as well as models of reduced immune function. Our results could lay the groundwork for development of an efficacious vaccine to prevent SA infection and limit pathogenesis. This vaccine could significantly improve the health of patients who suffer from invasive SA infections.

项目摘要：金黄色葡萄球菌 (SA)，包括耐甲氧西林 (MRSA)，是在美国，这是皮肤和软组织感染 (SSTI) 的最常见原因。 SA导致复发感染，特别是免疫功能降低的高度易感患者群体。到迄今为止，还没有预防 SA 感染的疫苗在人体试验中取得成功。同时，需要疫苗不断升级，这种病原体获得抗生素的能力也在不断升级反抗。我们开发了一种新型疫苗来控制 SA 毒力因子的调节生产。在皮肤感染模型中，这种疫苗会诱导产生抗体，防止激活这个调节系统可以防止侵入性感染。在本提案中，我们旨在评估该疫苗策略的临床前潜力。我们将在多个方面确定疫苗的功效 SA感染模型以及免疫功能下降模型。我们的结果可能奠定为开发有效疫苗预防SA感染和限制SA感染奠定基础发病。这种疫苗可以显着改善患有以下疾病的患者的健康侵袭性 SA 感染。